Amgen
Trade Amgen 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About AMGN
Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K.
AMGN Key Statistics
Stock Snapshot
As of today, Amgen(AMGN) shares are valued at $337.20. The company's market cap stands at 181.34B, with a P/E ratio of 26.03 and a dividend yield of 2.8%.
On 2025-11-15, Amgen(AMGN) stock moved within a range of $330.30 to $339.94. With shares now at $337.20, the stock is trading +2.1% above its intraday low and -0.8% below the session's peak.
Trading activity shows a volume of 3.31M, compared to an average daily volume of 3.3M.
Over the past 52 weeks, Amgen(AMGN) stock has traded between a high of $345.84 and a low of $253.30.
Over the past 52 weeks, Amgen(AMGN) stock has traded between a high of $345.84 and a low of $253.30.
AMGN News
Wondering if Amgen is a bargain right now? You are not alone. Investors are constantly on the lookout for stocks whose price might not reflect their true worth....
Below is Validea's guru fundamental report for AMGEN, INC. (AMGN). Of the 22 guru strategies we follow, AMGN rates highest using our P/B Growth Investor model b...
Blue Chips, Value-Oriented Firms Reign Over Market Gains; Is Leadership's Complexion Changing? 11/11/2025 Amgen's riveting 14% gain over five sessions stands i...
Analyst ratings
48%
of 33 ratingsMore AMGN News
Key Points An analyst bumped his price target higher on the shares. He didn't change his recommendation, however. 10 stocks we like better than Amgen › On T...
The Dow Jones Industrial Average finished on Tuesday with its 16th record close of the year. The Dow Jones Industrial Average ended Tuesday’s session at an all...
These three healthcare stocks are outperforming most of the sector. Healthcare stocks are hot right now. Several factors are driving them higher, including inn...
...
Amgen (AMGN) announced detailed results from the Phase 3 VESALIUS-CV clinical trial, which showed that Repatha achieved statistically significant and clinically...
Amgen recently reported strong third-quarter 2025 results, surpassing analyst expectations for revenue and earnings, and presented positive new Phase 3 clinical...